Japan approves Sanofi’s Sarclisa combo for MM treatment
Pharmaceutical Business Review
The approval follows a positive finding in the pivotal IRAKLIA Phase III study, which demonstrated non-inferior efficacy and pharmacokinetics compared with the intravenous (IV) formulation.
pharminent
June 22, 2026 (Last updated: June 22, 2026)
Pharmaceutical Business Review
The approval follows a positive finding in the pivotal IRAKLIA Phase III study, which demonstrated non-inferior efficacy and pharmacokinetics compared with the intravenous (IV) formulation.
